Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now…
(TheNewswire) VANCOUVER, BC, September 23, 2024 Heritage Mining Ltd. (CSE: HML FRA:Y66) (‘ Heritage ‘ or the ‘ Company ‘)…
The S&P/TSX Venture Composite Index (INDEXTSI:JX) gained 35.21 points this week to close at 580.43. Meanwhile, the S&P/TSX Composite…
Commodities giant BHP (ASX:BHP,NYSE:BHP,LSE:BHP) announced on Wednesday (September 18) that it will partner with the Meewasin Valley Authority on…
western copper and gold corporation (‘Western’ or the ‘Company’) (TSX: WRN) (NYSE American: WRN) welcomes the recent announcement by…
Sierra Nevada Gold (ASX: SNX) is pleased to announce it has staked two additional projects prospective for high-grade silver-gold-copper…
All eyes were on interest rates this week as the US Federal Reserve’s two day meeting took place. Meanwhile,…
West High Yield (W.H.Y.) Resources Ltd. (TSXV: WHY) (the ‘Company‘ or ‘West High Yield’) is pleased to announce that,…
Warren Buffett has a formidable reputation as an investor — with a current net worth of nearly US$134 billion,…